• Quotes
  • Shortcuts
The Executive's Internet
Tues, Jan 25th
icon
GoogleAmazonWikipedia


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Omicron COVID-19'. (Return)

MarketWatch MarketPulseJan 25, 2022
Pfizer and BioNTech launch study to evaluate omicron-based COVID-19 vaccine for adults 18 to 55 years old
Pfizer Inc. and German partner BioNTech SE said Tuesday they are launching a trial to evaluate an omicron-based COVID-19 vaccine in healthy adults aged 18 to 55. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," said Kathrin U. Jansen, Ph.D., senior vice president and head of vaccine R&D at Pfizer. The study will enroll up to $1,420 participants for three cohorts; one will comprise people who received two doses of the current Pfizer/BioNTech COVID vaccine 90 to 180 days prior to enrollment, with that group to receive one or two doses of the omicron vaccine; one comprised of people who received three doses of the existing vaccine and will get one dose of the current one or omicron one; and a third group of "vaccine-naive" people, who will get three doses of the omicron vaccine. Pfizer shares were down 1.1% premarket, while BioNTEch was down 0.8%. BioNTech remain up 36.5% in the last 12 months, while the SPDR S&P Biotech ETF has fallen 41% and the S&P 500 has gained 14%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



KiplingerJan 25, 2022
What to Expect from the 2022 Summer Travel Season
When Katie Knox, of East Lansing, Mich., booked a flight to Paris to visit her boyfriend over the holidays, she locked in a low fare on budget airline Frenchbee. But then her boyfriend tested positive for COVID-19 only days ahead of her planned departure, delaying her trip by 10 days. She changed her flight, but her sad saga was just beginning. Her Delta Airlines flight from Detroit to Newark, N.J., where she was connecting with her flight to Paris, was canceled, thanks to COVID-related staff shortages.

Knox had to wait a day to get another flight to Newark. She spent the night in a Detroit airport hotel and decided to book a new flight with Swiss Air from New York to Copenhagen, where her boyfriend was traveling to be with his family. She received a credit for her Frenchbee flight and booked a return flight home on Iceland Air. But that flight was canceled because of severe weather in Reykjavik. She opted for a refund instead of a new flight—but because she had booked the flight on travel aggregator Gotogate, she had to spend 10 hours on the phone, on hold and on multiple calls, trying to lock in the money. In the end she was promised the refund—which she was told could be delayed up to a year.

Welcome to travel in 2022. After two years of navigating the complexities of canceled, interrupted or delayed plans, thanks to the pandemic and its many ripples and waves, as well as severe weather, travelers endured another episode of canceled flights over the holidays. Now, many people have their sights set on traveling freely again this summer. But with COVID-related uncertainty, locking in travel itineraries may feel like wishful thinking.

Even so, travel experts are anticipating a rebound for tourism this summer, particularly in places where borders are just beginning to reopen. Many public health experts are predicting a relatively quick end to the omicron surge. And even if the virus sees a new surge from a new variant, the key to successful tr


Google Market NewsJan 25, 2022
Pfizer begins testing omicron-matched COVID shots in adults - Associated Press
Pfizer begins testing omicron-matched COVID shots in adults  Associated PressPfizer and BioNTech begin clinical trial for Omicron-specific vaccine  CNNPfizer, BioNTech begin omicron-specific COVID-19 vaccine study  Fox BusinessPfizer Begins Study Testing Omicron Vaccine in People  The Wall Street JournalPfizer starting trial for Omicron-specific Covid-19 vaccine  CNNView Full Coverage on Google News
TRENDING TAGS
StockMarket Buy Earnings Street Wall
StocksBuy Market S&P Dow Growth
WallStreet Stock stocks day Journal
StreetWall Stock stocks day Journal
TaxIRS Season credit child Know
Marketstock Futures Stocks Dow know
yeartax last meeting return Will
ChinaIMF Growth cuts global forecast
TodayStock Stocks Shares Again Higher
billionbillionaire GM bid Year Michigan

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2022 CEOExpress Company LLC